Cargando…

Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)

Detalles Bibliográficos
Autores principales: Mazur, Izabela, Elgamal, Mohamed, Mikulandric, Nancy, Neme, Klodiana, German, Angela Michael, Emole, Josephine, Abidi, Muneer H., Peres, Edward, Ramesh, Mayur, Farhan, Shatha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930043/
http://dx.doi.org/10.1016/S2666-6367(22)00295-0
_version_ 1784670976635568128
author Mazur, Izabela
Elgamal, Mohamed
Mikulandric, Nancy
Neme, Klodiana
German, Angela Michael
Emole, Josephine
Abidi, Muneer H.
Peres, Edward
Ramesh, Mayur
Farhan, Shatha
author_facet Mazur, Izabela
Elgamal, Mohamed
Mikulandric, Nancy
Neme, Klodiana
German, Angela Michael
Emole, Josephine
Abidi, Muneer H.
Peres, Edward
Ramesh, Mayur
Farhan, Shatha
author_sort Mazur, Izabela
collection PubMed
description
format Online
Article
Text
id pubmed-8930043
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-89300432022-03-18 Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706) Mazur, Izabela Elgamal, Mohamed Mikulandric, Nancy Neme, Klodiana German, Angela Michael Emole, Josephine Abidi, Muneer H. Peres, Edward Ramesh, Mayur Farhan, Shatha Transplant Cell Ther (Pharm) Pharmacy Nia Grant Update and Best Abstracts American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2022-03 2022-03-18 /pmc/articles/PMC8930043/ http://dx.doi.org/10.1016/S2666-6367(22)00295-0 Text en Copyright © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle (Pharm) Pharmacy Nia Grant Update and Best Abstracts
Mazur, Izabela
Elgamal, Mohamed
Mikulandric, Nancy
Neme, Klodiana
German, Angela Michael
Emole, Josephine
Abidi, Muneer H.
Peres, Edward
Ramesh, Mayur
Farhan, Shatha
Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
title Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
title_full Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
title_fullStr Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
title_full_unstemmed Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
title_short Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
title_sort poor humoral response to sars-cov-2 vaccination early after hematopoietic cell transplantation: interim results of prospective study (nct04723706)
topic (Pharm) Pharmacy Nia Grant Update and Best Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930043/
http://dx.doi.org/10.1016/S2666-6367(22)00295-0
work_keys_str_mv AT mazurizabela poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT elgamalmohamed poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT mikulandricnancy poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT nemeklodiana poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT germanangelamichael poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT emolejosephine poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT abidimuneerh poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT peresedward poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT rameshmayur poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706
AT farhanshatha poorhumoralresponsetosarscov2vaccinationearlyafterhematopoieticcelltransplantationinterimresultsofprospectivestudynct04723706